AstraZeneca shares rise
AstraZeneca shares rise as China probe update reassures
AstraZeneca shares rose on Thursday after the drugmaker said it could face a fine of up to $4.5 million in China over suspected unpaid import taxes for two cancer drugs, reassuring analysts and investors that the business impact would be minor.
AstraZeneca’s shares rise as it addresses China investigation
In addition to the UK investment controversy, AstraZeneca is also dealing with legal challenges in China. The company confirmed that its Chinese business is under investigation for alleged unpaid import taxes on certain cancer drugs, including Imfinzi (durvalumab) and Imjudo (tremelimumab).
AstraZeneca faces potential fines in China
Pharma giant AstraZeneca urged Britain to improve the environment for businesses in order to drive investment, days after it ...
Lord Storey says he fears Merseyside was "not a high priority" on the government's growth agenda.
Q4 2024 Earnings Call Feb 06, 2025, 6:00 a.m. ET. Contents: Prepared Remarks. Questions and Answers. Call Participants ...
The boss of AstraZeneca Plc said he does not believe the UK is the worst place to invest, striking a conciliatory tone just ...
The pharmaceuticals major was boosted by high demand for its key drugs that offset a slight sales drop in China.
Despite the discontinuations, CEO Pascal Soriot said AstraZeneca’s December 2020 acquisition of Alexion was a “fantastic” ...
Pascal Soriot, chief executive of AstraZeneca, denied any rift with the Government over the decision, which it revealed ...
A fresh earnings release was the news development powering AstraZeneca's (NASDAQ: AZN) share price higher on Thursday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback